Bivision Pharmaceuticals

Executive Summary

Bivision Pharmaceuticals is a privately held Chinese ophthalmic company headquartered in Suzhou, founded in 2014. With 200-500 employees, the company has reached commercial stage by developing a dual portfolio of pharmaceutical treatments (small molecules and biologics) and medical devices targeting dry eye, glaucoma, and retinal disorders. Bivision aims to provide integrated diagnostic-to-treatment solutions, positioning itself as a specialized player in China's growing ophthalmology market. While financial details and specific product revenues remain undisclosed, its commercial presence suggests established market traction. The company's competitive edge lies in its combined pharma-device approach, which may offer synergies in patient management. However, as a private entity, transparency is limited, and valuation is estimated. Nonetheless, Bivision's focus on high-need eye conditions and China's aging population underpins its growth potential.

Upcoming Catalysts (preview)

• Q3 2026New product launch or pipeline advancement in dry eye or glaucoma70% success
• Q4 2026Partnership or licensing deal with a global ophthalmic company for China market access60% success
• TBDRegulatory approval of a novel ophthalmic device or drug candidate50% success